Shukra Pharmaceuticals share price today

Shukra Pharmaceuticals Ltd's share price was ₹79.87 at the close on 4 November 2026. It has been rising for 10 weeks. That is 81.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹29 and ₹80, and at that close it was at the high of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Shukra Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row.

Over the last 11 years the share price moved +30,619% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: best operating margin in 15 quarters, number of shareholders up 63% in a year and closed the week at a 52-week high.

1. Best operating margin in 15 quarters

   Operating margin was 90% in the June 2026 quarter, against 24% a year earlier.

2. Number of shareholders up 63% in a year

   35,007 shareholders in the September 2026 quarter, against 21,441 a year earlier.

3. Closed the week at a 52-week high

   ₹74.95 on 30 Oct 2026, the highest weekly close in a year.

For April to June 2026 (the quarter ended 30 June 2026), Shukra Pharmaceuticals reported revenue of ₹24.0 crore, up 380.0% from ₹5.00 crore a year earlier, and a profit of ₹15.0 crore, up 1,400.0% from ₹1.00 crore.

Shukra Pharmaceuticals results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Shukra Pharmaceuticals closed at ₹79.87 on 4 November 2026, up 94.9% from ₹40.97 a year earlier (7 November 2025) and up 31,848.0% over five years. Its highest weekly close since March 2016 was ₹79.87 on 4 November 2026.

Shukra Pharmaceuticals share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

516 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Shukra Pharmaceuticals closed at ₹79.87, up 6.6% on the week and up 29.2% on the month. 21 Sep 2026: ex-date for a dividend of ₹0.01 a share.

Earlier

• Results for April to June 2026: Revenue up 380.0% and profit up 1,400.0% on a year earlier.

Shukra Pharmaceuticals paid ₹0.01 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.01% at the ₹79.87 close on 4 November 2026. The last was a dividend of ₹0.01 a share, ex-date 21 September 2026.

Shukra Pharmaceuticals dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Shukra Pharmaceuticals Ltd paid out 2% of its profit as dividends in FY26, and it paid a dividend in 8 of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

Shukra Pharmaceuticals is on 3 of our India lists: Momentum stocks, Penny stocks and Pharma stocks.

Shukra Pharmaceuticals Ltd earned ₹15.0 Cr of net profit in the Jun 2026 quarter, +1,400.0% on the same quarter a year earlier. Full-year FY26 profit was ₹22.0 Cr. That is 62.5% of the quarter's revenue. The same quarter a year earlier earned ₹1.0 Cr. 1 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹22.0 Cr (+120.0% on the year before).

Why profit moved: revenue changed +380.0% on a year earlier and the margin moved +66.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +481.7% and revenue +145.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Shukra Pharmaceuticals Ltd reported ₹24.0 Cr of revenue in the Jun 2026 quarter, +380.0% on the same quarter a year earlier. Over 10 years it has grown 27.6% a year on average. The last full year, FY26, came in at ₹57.0 Cr. The last four reported quarters add to ₹75.0 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹57.0 Cr, +72.7% on the year before.

Recent pace: the last four quarters grew +145.2% on average, against 27.6% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +114.3%, against +13.7% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +250.0%, against +39.4% a year (accelerating).

Shukra Pharmaceuticals Ltd's operating margin was 90.0% in the Jun 2026 quarter, 66.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −10.0% and 51.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +65.7 percentage points on the year while gross margin changed +20.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 12% of Shukra Pharmaceuticals Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹3.0 Cr of operating cash against ₹22.0 Cr of profit. After ₹16.0 Cr of spending on assets, free cash was −₹13.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Shukra Pharmaceuticals Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹57.0 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹20.0 Cr on assets over the last 3 years.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Averaged over those years that is 11.7% of FY26 revenue a year.

Spending on assets: ₹20.0 Cr over the last 3 years, against ₹8.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹12.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Shukra Pharmaceuticals Ltd's P/E is 98.0×, near the high end of its own history: higher than 84% of past readings. Its usual P/E (the middle reading) is 42.3×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.